Identification of an immunogenic 18 kDa protein of Helicobacter pylori using alkaline phosphatase gene fusions

Jane Oliaro

A thesis presented in partial fulfillment of the requirement for the Doctor of Philosophy in Molecular Microbiology

Massey University, Palmerston North, NZ

December, 1999
Abstract

Secreted or surface-associated proteins play an important role in the immunopathogenesis of *Helicobacter pylori* infection. The aim of this study was to identify, using a genetic approach, *H. pylori* exported proteins and assess their role in the host immune response to infection. As part of this work, an *H. pylori* expression library was constructed and screened with a monoclonal antibody raised to a component of outer membrane vesicles from *H. pylori*, identified and characterised in a separate study. The screening strategy identified a locus of the genome containing two genes encoding exported proteins. Subsequent expression studies identified the gene product detected by the antibody as Lpp20, which encodes a well characterised lipoprotein from *H. pylori*. In addition, the use of alkaline phosphatase (AP) gene fusion methodology enabled the identification of a large number of other *H. pylori* exported proteins. Immunoscreening of a selection of enzymatically active *H. pylori* AP fusion proteins was carried out by Western blot analysis with patient sera and lymphocyte proliferation assays using peripheral blood mononuclear cells from *H. pylori* infected individuals. These assays identified a novel *H. pylori* exported antigen which was recognised by antibody derived from *H. pylori* infected individuals. Southern blot analysis revealed that the gene encoding the protein was absent in other *Helicobacter* species tested and sequence analysis of the gene demonstrated that it is highly conserved among *H. pylori* isolates. In order to obtain pure recombinant protein, the gene encoding the protein was cloned and expressed as a Beta-galactosidase (β-gal) fusion in *Escherichia coli* and the protein purified by affinity chromatography. The size of the recombinant protein released (18 kDa) was consistent with the calculated molecular mass of the polypeptide deduced from the DNA sequence. In Western blot assays, the purified protein was recognised by 71% of sera taken from patients infected with *H. pylori*, but by only 16% of sera taken from patients with unrelated or with no gastrointestinal disease. These results indicated that the 18 kDa protein from *H. pylori* was immunogenic and expressed *in vivo*. In other experiments, it was found that oral administration of this antigen did not protect mice against *H. pylori* colonisation following challenge with *H. pylori*. 
Acknowledgements

I wish to thank Professor Bill Manktelow, former Head of the Department of Veterinary Pathology, for allowing me the opportunity to undertake a postgraduate degree in this Institute. I am also grateful to my chief supervisor, Dr Alan Murray, not only for his support and advice during this PhD project, but also for having the faith to take me on as a new graduate and allowing me the opportunity to grow and learn in the world of academia. I am also like to thank my second supervisor, Dr Paul O’Toole, whose expertise in the field has been invaluable. A special mention goes to Dr. Richard Johnson, my supervisor at the start of the project, for his contribution to the work and friendship over the years.

I would like to acknowledge the outstanding contribution of our collaborators at the Wakefield Gastroenterology Research Unit, Wellington. I would like to thank Dr Vinton Chadwick, for his guidance and encouragement throughout the project, and whose knowledge and expertise always kept me on my toes. With sincere gratitude I acknowledge Dr Wangxue Chen and Dairu Shu for performing the lymphocytes proliferation assays detailed in Chapter five, and the mouse immunisation trial in Chapter six. A special thanks to Chen, not only for his excellent scientific advice, but also for his friendship and willingness to assist.

I would also like to acknowledge Brigitte Gicquelt, of the Unite de Genetique Mycobacterienne., Pasteur Institute, Paris, France, for graciously providing the pJEM11 plasmid, without which this project would not have existed. I am also grateful to the The Lottery Health Board, The Palmerston North Medical Research Foundation, The Rose Catherine Hopkins Memorial Scholarship and The Health Research Council of New Zealand for funding this research.

A big thank you to my dear friends Dr Eamonn Gormley and Dr Suzanne Borich who are now many miles away, but never far from my thoughts. I couldn’t have done it without you Eamonn, thank you for keeping me smiling and for all the good times we have shared over the years. Thanks also to Stan Fenwick, for providing me with numerous opportunities to unwind at his many memorable parties. I would like to thank to each of my lab coworkers, both past and present; Chris, Hassan, Jeremy, Laurie,
Linley, Liz, Sandy, and Miho, for their companionship and always helpful advice. Thank you also to the Virology group; Magda, Darelle, Joanne and Matthew for their friendly advice and help over the years. A special thank you to Dr John Lumsden, for his patient assistance in helping me unravel the mysteries of lymphocyte proliferation assays. I am also grateful to Andrew Rowatt, for his immediate attention to all my computer crises. So many people in the Institute deserve a special mention, too many to list individually, so I collectively thank you all for the friendships and memories I have gathered over the years.

Finally, a very special thank you to my family. To Carl, for his infinite patience and support, and to my little princess, Tamara, who has brought more joy to my life than I ever thought imaginable. It has been a long but truly unforgettable journey.

This thesis is dedicated to my parents.
# Table of Contents

**Abstract** .................................................................................................................. I

**Acknowledgements** ................................................................................................... II

**Table of Contents** ...................................................................................................... IV

**List of Figures** .......................................................................................................... IX

**List of Tables** ........................................................................................................... XII

**Chapter 1 Introduction** ............................................................................................. 1

1.1 Gastrointestinal disease ......................................................................................... 1

1.1.1 Historical background ......................................................................................... 1

1.1.2 The discovery of *Helicobacter pylori* ................................................................. 2

1.2 *Helicobacter* species .............................................................................................. 3

1.2.1 Classification ........................................................................................................ 3

1.2.2 The *H. pylori* genome ......................................................................................... 3

1.3 *Helicobacter pylori* infection in humans ............................................................... 4

1.3.1 Epidemiology ...................................................................................................... 4

1.3.2 Clinical manifestations ......................................................................................... 6

1.3.2.1 Gastritis and peptic ulcer disease ................................................................. 6

1.3.2.2 *H. pylori* associated neoplasia ................................................................. 8

1.3.2.3 Extradigestive diseases .................................................................................. 10

1.4 Pathogenesis of infection ....................................................................................... 10

1.4.1 Colonisation and persistence in the gastric mucosa ........................................... 10

1.4.2 Virulence factors ............................................................................................... 12

1.5 Diagnosis and treatment ......................................................................................... 14

1.5.1 Diagnosis of *Helicobacter pylori* infection ..................................................... 14

1.5.2 Treatment of *Helicobacter pylori* infection .................................................... 15

1.6 *Helicobacter* infection in animals ......................................................................... 16

1.6.1 Natural infection ................................................................................................. 16

1.6.2 Animal models .................................................................................................... 17

1.7 The immune response to *Helicobacter* infection ................................................ 19

1.7.1 Innate immunity ................................................................................................ 19

1.7.2 Acquired immunity ............................................................................................ 24

1.7.2.1 Cell-mediated immunity .............................................................................. 25

1.7.2.2 Antibody-mediated immunity .................................................................... 29

1.8 Vaccination against *H. pylori* infection ............................................................... 31

1.9 Secretion of bacterial virulence factors .................................................................. 35
Table of Contents

1.9.1 Bacterial secretion systems ................................................................................... 35
  1.9.1.1 Type I secretion ....................................................................................... 35
  1.9.1.2 Type II secretion ..................................................................................... 37
  1.9.1.3 Type III secretion ................................................................................... 41
  1.9.1.4 The Autotransporters ............................................................................. 42
  1.9.1.5 Type IV secretion .................................................................................... 44
1.9.2 Secretion of *H. pylori* proteins ............................................................................. 45
  1.9.2.1 Outer membrane vesicles of *H. pylori* .................................................. 48
1.10 Aims of the thesis .............................................................................................................. 49

Chapter 2 General Materials and Methods ................................................................................. 50

2.1 Bacterial strains and plasmids .............................................................................................................. 50
  2.1.1 Bacterial strains .............................................................................................. 50
  2.1.2 Plasmids and phagemids ................................................................................... 51
2.2 Bacterial growth conditions .............................................................................................................. 51
2.3 DNA extractions .............................................................................................................................. 52
  2.3.1 Isolation of plasmid DNA from *E. coli* .......................................................... 52
  2.3.2 Isolation of genomic DNA from *Helicobacter* species ....................................... 53
2.4 DNA manipulations .......................................................................................................................... 53
  2.4.1 Ethanol precipitation of DNA ......................................................................... 53
  2.4.2 Electrophoresis ................................................................................................. 53
  2.4.3 Cloning procedures ........................................................................................... 53
2.5 Transformations ............................................................................................................................. 55
  2.5.1 Preparation of competent cells ........................................................................ 55
  2.5.2 Transformation of *E. coli* .............................................................................. 55
2.6 Polymerase chain reaction ............................................................................................................... 56
  2.6.1 Primer design ..................................................................................................... 56
  2.6.2 PCR conditions .................................................................................................. 56
2.7 DNA sequencing ............................................................................................................................ 57
  2.7.1 Manual sequencing ........................................................................................... 57
  2.7.2 Automated sequencing ...................................................................................... 58
  2.7.3 Sequence analyses ............................................................................................ 58
2.8 DNA hybridisations ........................................................................................................................ 59
  2.8.1 Isolation and labeling of DNA probes .............................................................. 59
  2.8.2 Southern blot analysis ....................................................................................... 60
2.9 Protein preparations ....................................................................................................................... 61
  2.9.1 Preparation of *E. coli* lysate .......................................................................... 61
Chapter 4 Identification of H. pylori DNA Sequences Encoding Exported Proteins

4.1 Abstract .........................................................................................................................90
4.2 Introduction ....................................................................................................................90
4.3 Materials and methods ...............................................................................................93
  4.3.1 Construction of an H. pylori exported protein library ............................................93
  4.3.2 Screening of the pJMEM11 library for known H. pylori gene sequences ..................95
  4.3.3 Analysis of H. pylori alkaline phosphatase fusions ..................................................95
4.4 Results .........................................................................................................................98
Table of Contents

4.4.1 Construction and screening of an *H. pylori* library of AP fusions .................. 98
4.4.2 Screening of the *H. pylori* AP fusion library for known *H. pylori* gene sequences ................................................................................................................................. 100
4.4.3 Sequencing of the *H. pylori* DNA inserts encoding exported proteins .......... 101
4.4.4 Detection of AP fusion proteins from recombinant *E. coli* ......................... 110
4.5 Discussion .............................................................................................................. 111

Chapter 5 Biochemical and Immunological Analysis of *E. coli* Alkaline Phosphatase Fusion Proteins ................................................................. 117

5.1 Abstract .............................................................................................................. 117
5.2 Introduction ........................................................................................................ 117
5.3 Material and methods ....................................................................................... 119
  5.3.1 Isolation of periplasmic space proteins .......................................................... 119
  5.3.2 Enzyme assays ............................................................................................... 120
  5.3.3 Western blotting ............................................................................................ 121
  5.3.4 Immunoassays ............................................................................................... 121
5.4 Results .............................................................................................................. 123
  5.4.1 Isolation of periplasmic space proteins enriched for *H. pylori* AP fusion proteins ................................................................................................................................. 123
  5.4.2 Determination of the purity of the periplasmic space proteins by Western blot analysis ................................................................................................................................. 124
  5.4.3 Alkaline phosphatase and β–galactosidase enzyme activity in
  *E. coli* cellular fractions ..................................................................................... 126
  5.4.4 Antibody recognition of *H. pylori* AP+ fusion proteins ............................ 127
  5.4.5 Sequence analysis of the plasmid pJHp20 .................................................... 129
  5.4.6 Enzyme activity in cellular fractions from cultures of *E. coli* pJHp20 ...... 130
  5.4.7 Peripheral blood lymphocyte response to *H. pylori* AP+ fusion proteins .......... 130
5.5 Discussion .......................................................................................................... 133

Chapter 6 Cloning and Heterologous Expression of an Immunogenic Protein from *H. pylori* ................................................................................... 136

6.1 Abstract .............................................................................................................. 136
6.2 Introduction ....................................................................................................... 136
6.3 Materials and methods ..................................................................................... 138
  6.3.1 Polymerase chain reaction ........................................................................... 138
  6.3.2 Southern blot analysis ................................................................................ 139
  6.3.3 Expression and purification of the 18 kDa protein ...................................... 139
Table of Contents

6.3.4 Western blot analysis ................................................................. 141
6.3.5 Patient samples .............................................................................. 142
6.3.6 Mouse immunisation protocol ............................................................ 142

6.4 Results .......................................................................................... 144
6.4.1 Distribution of the HP1085 gene among Helicobacter species .......... 144
6.4.2 Conservation of the HP1085 gene among H. pylori strains .......... 145
6.4.3 Sequence analysis of the HP1085 gene ........................................... 146
6.4.4 Expression and purification of the 18 kDa protein ......................... 147
6.4.5 Humoral immune response to the purified 18 kDa protein .......... 148
6.4.6 Oral immunisation using recombinant 18 kDa antigen in a mouse model 149

6.5 Discussion .................................................................................. 151

Chapter 7 Concluding Comments .......................................................... 156

Appendices ....................................................................................... 160
Appendix A Raw data for enzyme assays in Chapter 5 ......................... 160
Appendix B Raw data for mouse immunisation trial in Chapter 6 ......... 162
Appendix C One letter codes for amino acids and deoxyribonucleosides 162
Appendix D List of publication related to this thesis .............................. 163

References .......... .............................................................................. 164
List of Figures

**Figure 1.1** Schematic representation of the host immune response to *H. pylori* infection ............... 21

**Figure 1.2** Schematic overview of the Type I, II, III and IV secretion pathways .......................... 36

**Figure 3.1** Schematic representation of cloning of HP1456 and HP1457 into two expression vectors, pGEX-6P-3 and pPROEX HTb showing the major features of each vector ....................... 75

**Figure 3.2** Comparison of protein profiles from an *H. pylori* type strain NCTC 11637 and the human clinical isolate (NZCH1) used in this study ................................................................. 76

**Figure 3.3** Autoradiograph of Western blot analysis of *H. pylori* NZCH1 lysate protein screened with sera from an *H. pylori* ser-positive and sero-negative patient ...................................... 77

**Figure 3.4** Southern blot experiments to detect the *cag A* and *vac A* gene in *H. pylori* genomic DNA .......................................................................................................................... 78

**Figure 3.5** Western blots of *H. pylori* and *E. coli* lysate protein screened with anti-VacA antibody and anti-CagA antibody ........................................................................................................ 79

**Figure 3.6** Southern blot screening of the *H. pylori* expression library ....................................... 81

**Figure 3.7** Secondary screening of the *H. pylori* lambda library with a monoclonal antibody raised to an 18 kDa antigen from membrane vesicles of *H. pylori* ........................................ 82

**Figure 3.8** Schematic representation of the *H. pylori* insert sequence from a positive phagemid following screening with a monoclonal antibody ......................................................... 82

**Figure 3.9** Expression of HP1457 in pPROEX HTb resulting in a 27.8 kDa fusion protein consisting of HP1457 and a six Histidine tag (6.8 kDa) for affinity purification ............................... 83

**Figure 3.10** Identification of HP1456 with an anti-18 kDa monoclonal antibody ............................ 84

**Figure 4.1** Map of the plasmid vector pJEM11 showing the major features ..................................... 92

**Figure 4.2** Schematic representation of the location of the oligonucleotide primers designed to sequence the *H. pylori* insert within the pJEM11 vector ..................................................... 97

**Figure 4.3** Schematic representation of the pJEM11 AP fusion library ........................................... 98
List of Figures

**Figure 4.4** Recombinant *E. coli* pJEM11 *H. pylori* recombinant colonies ............................................. 99

**Figure 4.5** Autoradiograph of Southern blot screening of the pJEM11 *H. pylori* library with the vacA gene probe ................................................................................................................................. 100

**Figure 4.6** PCR amplification of thirty-five blue *E. coli* pJEM11 *H. pylori* recombinant plasmids ................................................................................................................................. 101

**Figure 4.7** Kyte-Doolittle (KD) plot of three integral membrane proteins .............................................. 102

**Figure 4.8** Kyte-Doolittle plot of HP1117, an *H. pylori* periplasmic protein, and HP0896, an outer membrane protein (omp19) identified by sequencing of the *H. pylori* inserts in recombinant blue pJEM11 clones ...................................................................................................... 104

**Figure 4.9** DNA sequence alignment between pJHp5/9 and the HP0214 open reading frame showing the region of homology ........................................................................................................ 107

**Figure 4.10** KD hydropathy plot of HP0214 translated from the potential start codon fused in-frame with the phoA gene ............................................................................................................................................ 108

**Figure 4.11** Predicted promoter sequences for *H. pylori* ORFs identified in the pJEM11 library ....................................................................................................................................................... 109

**Figure 4.12** Western blot analysis of lysate protein from various blue recombinant pJEM11 *H. pylori* clones screened with a polyclonal antibody raised against alkaline phosphatase .......................... 110

**Figure 5.1** Western blot analysis of selected *H. pylori* AP fusion proteins .................................................. 123

**Figure 5.2** Alkaline phosphatase activity in periplasmic space protein fractions isolated from *H. pylori* pJEM11 recombinant clones and controls ........................................................................................................ 124

**Figure 5.3** Coomassie stain of intracellular and periplasmic space proteins from pJHp blue colonies and alkaline phosphatase control. Autoradiograph of Western blot ...................................................... 125

**Figure 5.4** Alkaline phosphatase and Beta-galactosidase enzyme assays for cellular fractions derived from *E. coli* pJHp clones and controls ........................................................................................................ 126

**Figure 5.5** Western blot analysis of periplasmic (PS) protein from *E. coli* pJHp recombinant clones screened with pooled sera from *H. pylori* infected patients ...................................................................................................................... 127
Figure 5.6 Western blot analysis of pJHp20 and controls screened with pooled sera from H. pylori infected patients or a polyclonal antibody raised against alkaline phosphatase .........................128

Figure 5.7 Western blot analysis of pJHp10 with individual sera from five H. pylori infected patients ........................................................................................................................................129

Figure 5.8 Schematic diagram of pJHp20 .........................................................................................................................................................................................129

Figure 5.9 Alkaline phosphatase and Beta-galactosidase activity in pJHp20 cellular fractions...130

Figure 6.1 PCR amplification of the HP1085 gene from Helicobacter species .......................144

Figure 6.2 Southern blot of genomic DNA from Helicobacter species, using the HP1085 gene PCR product as a probe .........................................................................................................................................................................................145

Figure 6.3 Kyte-Doolittle plot of the 18 kDa protein and signal sequence features of the N-terminal region of the 18 kDa protein showing the predicted domains and cleavage site...........146

Figure 6.4 Expression of the Beta-galactosidase HP1085 fusion protein.................................147

Figure 6.5 Cleavage and purification of the 18 kDa antigen from Beta-galactosidase .............148

Figure 6.6 Western blot purified recombinant 18 kDa protein screened with sera from H. pylori infected and non-infected individuals .........................................................................................................................149

Figure 6.7 Mean log CFU/g stomach tissue for each group of mice. Mice were either non-immunised (controls) or immunised with PBS, H. pylori sonicate or the 18 kDa antigen ..........150

Figure 6.8 Gastric tissue urease test for each group of mice. The number of mice positive for urease activity was plotted as a percentage of total number for each group of mice immunised with either PBS, H. pylori sonicate or the 18 kDa antigen, in addition to non-immunised controls .........................................................................................................................................................................................150
## List of Tables

<table>
<thead>
<tr>
<th>Table</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Table 2.1</td>
<td>Bacterial strains used in this study</td>
<td>50</td>
</tr>
<tr>
<td>Table 2.2</td>
<td>Plasmids used in this study</td>
<td>51</td>
</tr>
<tr>
<td>Table 2.3</td>
<td>Media supplements and antibiotics</td>
<td>52</td>
</tr>
<tr>
<td>Table 2.4</td>
<td>Patient data for sera used in this study</td>
<td>65</td>
</tr>
<tr>
<td>Table 3.1</td>
<td>Oligonucleotide primers designed to amplify <em>H. pylori</em> gene sequences</td>
<td>71</td>
</tr>
<tr>
<td>Table 3.2</td>
<td>Oligonucleotide primers designed to amplify HP1456 and HP1457</td>
<td>74</td>
</tr>
<tr>
<td>Table 4.1</td>
<td>Oligonucleotide primers designed to the pJEM11 vector</td>
<td>96</td>
</tr>
<tr>
<td>Table 4.2</td>
<td>Open reading frames (ORFs) with start codon in-frame with <em>phoA</em>, identified by sequencing of pJEM11 <em>H. pylori</em> insert DNA from recombinant blue colonies</td>
<td>103</td>
</tr>
<tr>
<td>Table 4.3</td>
<td>Open reading frames (ORFs) with part of a gene fused to <em>phoA</em>, identified by sequencing of pJEM11 <em>H. pylori</em> insert DNA from recombinant blue colonies</td>
<td>105</td>
</tr>
<tr>
<td>Table 5.1</td>
<td>Lymphocyte proliferation assays A</td>
<td>131</td>
</tr>
<tr>
<td>Table 5.2</td>
<td>Lymphocyte proliferation assays B</td>
<td>132</td>
</tr>
<tr>
<td>Table 6.1</td>
<td>Antibody titres in mice post-immunisation</td>
<td>151</td>
</tr>
</tbody>
</table>